Filing Details
- Accession Number:
- 0001209191-10-051873
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-10-27 17:35:40
- Reporting Period:
- 2010-10-27
- Filing Date:
- 2010-10-27
- Accepted Time:
- 2010-10-27 17:35:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1338042 | Aegerion Pharmaceuticals Inc. | AEGR | Pharmaceutical Preparations (2834) | 202960116 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1227759 | Advent International Llc | C/O Advent International Corporation 75 State Street, 29Th Floor Boston MA 02109 | No | No | No | Yes |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2010-10-27 | 1,249,350 | $0.00 | 1,253,473 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2010-10-27 | 436,498 | $0.00 | 1,689,971 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2010-10-27 | 805,140 | $7.60 | 2,495,111 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2010-10-27 | 260,263 | $9.50 | 2,755,374 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Convertible Preferred Stock | Disposition | 2010-10-27 | 3,228,204 | $0.00 | 1,249,350 | $0.00 |
Common Stock | Series B Convertible Preferred Stock | Disposition | 2010-10-27 | 715,247 | $0.00 | 436,498 | $0.00 |
Common Stock | Senior Subordinated Convertible Promissory Notes | Disposition | 2010-10-27 | 0 | $0.00 | 805,140 | $7.60 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | 2011-12-31 | No | 4 | C | Indirect |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 4,123 | Indirect | See Footnote |
Footnotes
- These securities are indirectly beneficially owned in the following capacities; as General Partner of AHLS III GP, which in turn is the General Partner of Advent Healthcare & Life Sciences III Limited Partnership and Advent Healthcare & Life Science III A Limited Partnership.
- Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares") and each share of the Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, immediately converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. The Series A Shares converted on a 1-for-0.38701117412 basis and the Series B Shares converted on a 1-for-0.61027657931 basis. The Series A Shares and the Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date.
- Shares acquired upon the closing of the Issuer's initial public offering at the initial public offering price of $9.50 per share.
- The outstanding principal and accrued and unpaid interest on these senior subordinated convertible promissory notes (the "Convertible Notes") automatically converted into shares of common stock upon the closing of the Issuer's initial public offering, at $7.60 per share, 80% of the Issuer's initial public offering price per share.